Welcome to a new report of my Dividend Diary on the TEV Blog. Here, I report the development of a cash flow-oriented investment approach that focuses on generating a passive income through dividends. Against this background, the goal is not to outperform the market but to put food on the table through a regular income via dividends.
With the Dividend Diary, I document how a cash-flow investment approach can be part of well-balanced wealth management. To keep things simple, I have built three pillars:
- Active income.
- Passive income.
- Conversion.
Dividends fall into the last two categories. They are passive because they provide a cash flow without me having to go to work. Additionally, they are an essential pillar for the conversion since they can be reinvested to generate even more income in the future. That is the Theory. Now let’s get down to practice.
My monthly income through dividends in February:
This month, my cash-flow approach generated the following income through dividends:
- AT&T (49.02 EUR)
- Bristol-Myers Squibb (31.61 EUR)
- CVS Health (7.52 EUR)
- General Mills (24.42 EUR)
- General Dynamics (7.14 EUR)
- Apple (7.51 EUR)
- Realty Income (6.96 EUR)
- Procter & Gamble (14.22 EUR)
- Kinder Morgan (13.44 EUR)
- AbbVie (31.42 EUR)
- Siemens (52.00 EUR)
- Omega Healthcare (23.48 EUR).
The total monthly income through dividends in February (after taxes) was: €268.74/appr. $302
Dividend income report check
Great financial performance compared to last year (+ 75 percent YoY) – but shitty month overall.
